Hongjiao Wu , Yuning Xie , Ang Li , Xiyao Liu , Liwen Guo , Fengjun Wu , Zhenbang Yang , Zhi Zhang , Xuemei Zhang
{"title":"LncRNA RNF144A-AS1 gene polymorphisms and their influence on lung cancer patients in the Chinese Han population","authors":"Hongjiao Wu , Yuning Xie , Ang Li , Xiyao Liu , Liwen Guo , Fengjun Wu , Zhenbang Yang , Zhi Zhang , Xuemei Zhang","doi":"10.1016/j.ncrna.2024.10.008","DOIUrl":null,"url":null,"abstract":"<div><div>Lung cancer is primarily classified as NSCLC, which is distinguished by a wide range of genetic variations. This study focused on <em>RNF144A-AS1</em>, a relatively unexplored lncRNA, to explore the impact of its genetic polymorphisms on the susceptibility to NSCLC. We detected <em>RNF144A-AS1</em> expression and its correlation with prognosis and clinical pathological features using bioinformatics analysis. The association between <em>RNF144A-AS1</em> polymorphism and NSCLC susceptibility was evaluated using case-control methods. This investigation featured a cohort of 700 NSCLC individuals and 700 healthy controls. The genotype of genetic variation was detected by PCR-RFLP and iMLDR, followed by subsequent calculation of <em>OR</em> and 95 % <em>CI</em>. Our data show that <em>RNF144A-AS1</em> exhibits high expression levels in LUAD tissues and its expression is closely linked to LUAD progression and prognosis. Carrier of <em>RNF144A-AS1</em> rs3806609 TT genotype increased NSCLC susceptibility compared to carrier of rs3806609 CC genotype (<em>OR</em> = 2.21, 95%<em>CI</em> = 1.57–3.13). Our study identifies <em>RNF144A-AS1</em> genetic variants as potential susceptibility markers in NSCLC. <em>RNF144A-AS1</em> promotes cell proliferation and migration in LUAD through the IFN-γ/JAK2/STAT1 signalling pathway. Collectively, these findings pave the way for developing targeted therapies and diagnostic tools based on <em>RNF144A-AS1</em> and its variants.</div></div>","PeriodicalId":37653,"journal":{"name":"Non-coding RNA Research","volume":"10 ","pages":"Pages 252-260"},"PeriodicalIF":5.9000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Non-coding RNA Research","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468054024001513","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lung cancer is primarily classified as NSCLC, which is distinguished by a wide range of genetic variations. This study focused on RNF144A-AS1, a relatively unexplored lncRNA, to explore the impact of its genetic polymorphisms on the susceptibility to NSCLC. We detected RNF144A-AS1 expression and its correlation with prognosis and clinical pathological features using bioinformatics analysis. The association between RNF144A-AS1 polymorphism and NSCLC susceptibility was evaluated using case-control methods. This investigation featured a cohort of 700 NSCLC individuals and 700 healthy controls. The genotype of genetic variation was detected by PCR-RFLP and iMLDR, followed by subsequent calculation of OR and 95 % CI. Our data show that RNF144A-AS1 exhibits high expression levels in LUAD tissues and its expression is closely linked to LUAD progression and prognosis. Carrier of RNF144A-AS1 rs3806609 TT genotype increased NSCLC susceptibility compared to carrier of rs3806609 CC genotype (OR = 2.21, 95%CI = 1.57–3.13). Our study identifies RNF144A-AS1 genetic variants as potential susceptibility markers in NSCLC. RNF144A-AS1 promotes cell proliferation and migration in LUAD through the IFN-γ/JAK2/STAT1 signalling pathway. Collectively, these findings pave the way for developing targeted therapies and diagnostic tools based on RNF144A-AS1 and its variants.
期刊介绍:
Non-coding RNA Research aims to publish high quality research and review articles on the mechanistic role of non-coding RNAs in all human diseases. This interdisciplinary journal will welcome research dealing with all aspects of non-coding RNAs-their biogenesis, regulation and role in disease progression. The focus of this journal will be to publish translational studies as well as well-designed basic studies with translational and clinical implications. The non-coding RNAs of particular interest will be microRNAs (miRNAs), small interfering RNAs (siRNAs), small nucleolar RNAs (snoRNAs), U-RNAs/small nuclear RNAs (snRNAs), exosomal/extracellular RNAs (exRNAs), Piwi-interacting RNAs (piRNAs) and long non-coding RNAs. Topics of interest will include, but not limited to: -Regulation of non-coding RNAs -Targets and regulatory functions of non-coding RNAs -Epigenetics and non-coding RNAs -Biological functions of non-coding RNAs -Non-coding RNAs as biomarkers -Non-coding RNA-based therapeutics -Prognostic value of non-coding RNAs -Pharmacological studies involving non-coding RNAs -Population based and epidemiological studies -Gene expression / proteomics / computational / pathway analysis-based studies on non-coding RNAs with functional validation -Novel strategies to manipulate non-coding RNAs expression and function -Clinical studies on evaluation of non-coding RNAs The journal will strive to disseminate cutting edge research, showcasing the ever-evolving importance of non-coding RNAs in modern day research and medicine.